Dr. Leonard Saltz of Sloan Kettering thinks FOLFOX and FOLFIRI are equally meritorious in first-line metastatic colorectal cancer. He does not do any screening to select one or the other. FWIW
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”